Heineken Is Warning Pubs About Weight-Loss Drugs

Heineken is quietly telling British pubs something big is threatening their taps: weight-loss drugs. In a presentation seen by Reuters, the brewer warned UK hospitality clients that GLP-1 medications like Ozempic and Wegovy can curb the urge to drink by making people feel fuller and less interested in multi-pint sessions—potentially squeezing beer and cider sales. The world's second-largest brewer is advising venues to push half-pints, low- or no-alcohol options, and small-plate pairings to keep spending from sliding as the drugs go mainstream.

"If customers using these medicines begin ordering fewer full pints or visiting less often, the effect could go beyond one brewer," notes a post at Vinetur. "It could affect how pubs plan menus, manage stock, and shape promotions." Early data suggest the concern isn't theoretical: One US study found households with a GLP-1 user spent about 7% less on alcohol overall, and more than 13% less on beer, after two years. Reuters did its own survey and found that 10 of 11 GLP-1 users had cut down on their drinking, either because they had no desire for it, or because the drink made them feel unwell.